<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Polymers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Polymers (Basel)</journal-id><journal-id journal-id-type="publisher-id">polymers</journal-id><journal-title-group><journal-title>Polymers</journal-title></journal-title-group><issn pub-type="epub">2073-4360</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006176</article-id><article-id pub-id-type="pmc">PMC11859993</article-id><article-id pub-id-type="doi">10.3390/polym17040514</article-id><article-id pub-id-type="publisher-id">polymers-17-00514</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Development of Vaginal In Situ Gel Containing ISN/HP-&#x003b2;-CD Inclusion Complex for Enhanced Solubility and Antifungal Efficacy</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-9501-6863</contrib-id><name><surname>Alloush</surname><given-names>Tarek</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-polymers-17-00514" ref-type="aff">1</xref><xref rid="af2-polymers-17-00514" ref-type="aff">2</xref><xref rid="c1-polymers-17-00514" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8897-0885</contrib-id><name><surname>Yurtda&#x0015f; K&#x00131;r&#x00131;ml&#x00131;o&#x0011f;lu</surname><given-names>G&#x000fc;lsel</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-polymers-17-00514" ref-type="aff">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Cadenas-Pliego</surname><given-names>Gregorio</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-polymers-17-00514"><label>1</label>Institute of Health Sciences, Istanbul University, 34216 Istanbul, T&#x000fc;rkiye</aff><aff id="af2-polymers-17-00514"><label>2</label>Department of Pharmaceutical Technology, Graduate School of Health Sciences, Anadolu University, 26470 Eski&#x0015f;ehir, T&#x000fc;rkiye</aff><aff id="af3-polymers-17-00514"><label>3</label>Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, 26470 Eski&#x0015f;ehir, T&#x000fc;rkiye; <email>gyurtdas@anadolu.edu.tr</email></aff><author-notes><corresp id="c1-polymers-17-00514"><label>*</label>Correspondence: <email>tarek.alloush@ogr.iu.edu.tr</email>; Tel.: +90-5541949537</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>4</issue><elocation-id>514</elocation-id><history><date date-type="received"><day>15</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>09</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>12</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Many antifungal agents, including isoconazole nitrate (ISN), suffer from low aqueous solubility and inconsistent dissolution kinetics, which limit their therapeutic potential. To address these challenges, this study aimed to enhance the solubility and stability of ISN through the development of inclusion complexes with hydroxypropyl-&#x003b2;-cyclodextrin (HP-&#x003b2;-CD). HP-&#x003b2;-CD inclusion complexes were prepared using a spray-drying technique and characterized through phase-solubility studies, scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FT-IR), proton nuclear magnetic resonance (<sup>1</sup>H-NMR), and differential scanning calorimetry (DSC). The inclusion complex significantly improved ISN solubility, increasing from 0.5088 mg/mL to 3.6550 mg/mL. These complexes were incorporated into a thermosensitive, mucoadhesive in situ gel system using Pluronic<sup>&#x000ae;</sup> F127 and hydroxypropyl methylcellulose (HPMC) to optimize vaginal drug delivery. The formulations were evaluated for gelation temperature, viscosity, swelling behavior, and pH, confirming their suitability for vaginal application. Antimicrobial studies demonstrated that the ISN/HP-&#x003b2;-CD gels exhibited superior activity against <italic toggle="yes">Candida albicans</italic>, <italic toggle="yes">C. glabrata</italic>, and <italic toggle="yes">C. krusei</italic> compared to ISN alone. In vitro release studies further revealed sustained drug release following Peppas-Sahlin kinetics, supporting enhanced bioavailability and prolonged therapeutic action. This study demonstrates that the ISN/HP-&#x003b2;-CD-loaded in situ gel system offers a promising and effective approach for improving the solubility, stability, and antifungal efficacy of ISN for the treatment of vaginal infections.</p></abstract><kwd-group><kwd>isoconazole nitrate</kwd><kwd>solubility enhancement</kwd><kwd>hydroxypropyl-&#x003b2;-cyclodextrin</kwd><kwd>spray drying</kwd><kwd>inclusion complexes</kwd><kwd>in situ gel</kwd></kwd-group><funding-group><award-group><funding-source>Scientific Research Coordination Unit of Anadolu University</funding-source><award-id>1907S132</award-id></award-group><funding-statement>This research was supported by the Scientific Research Coordination Unit of Anadolu University (Project No: 1907S132).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-polymers-17-00514"><title>1. Introduction</title><p>Vaginal candidiasis, sometimes called vulvovaginal candidiasis, is a common vaginal mucosal infection that is mostly caused by the Candida species [<xref rid="B1-polymers-17-00514" ref-type="bibr">1</xref>,<xref rid="B2-polymers-17-00514" ref-type="bibr">2</xref>]. It is the second most frequent mucosal infectious condition after bacterial vaginosis. This condition affects a significant proportion of women worldwide, with more than 80% of women expected to experience a vaginal infection at least once in their lifetime [<xref rid="B1-polymers-17-00514" ref-type="bibr">1</xref>]. Symptoms such as itching, burning, irritation, and abnormal discharge can severely impact the quality of life [<xref rid="B3-polymers-17-00514" ref-type="bibr">3</xref>]. Additionally, recurrent vaginal candidiasis, affecting up to five percent of women, incurs substantial healthcare costs and poses a challenge for effective treatment [<xref rid="B4-polymers-17-00514" ref-type="bibr">4</xref>]. Traditional vaginal therapies, including creams, ointments, and semi-solid gels, are commonly used but are associated with significant limitations such as leakage, messiness, and insufficient retention in the vaginal cavity, leading to reduced therapeutic efficacy and patient compliance [<xref rid="B5-polymers-17-00514" ref-type="bibr">5</xref>].</p><p>Isoconazole nitrate (ISN), a broad-spectrum antifungal agent from the azole class, is widely used for the treatment of vaginal infections [<xref rid="B6-polymers-17-00514" ref-type="bibr">6</xref>,<xref rid="B7-polymers-17-00514" ref-type="bibr">7</xref>]. Its strong activity against Candida species and Gram-positive bacteria makes it a preferred choice for managing vaginal candidiasis. However, ISN has low aqueous solubility and is highly sensitive to environmental factors such as light and temperature, which limits its bioavailability and overall therapeutic potential (<xref rid="polymers-17-00514-f001" ref-type="fig">Figure 1</xref>a). These formulation challenges necessitate innovative strategies to improve ISN&#x02019;s solubility, stability, and retention in the vaginal cavity.</p><p>Recently, a lot of research has been conducted to increase the bioavailability of vaginal therapies. Cyclodextrins (CDs) are highly preferred because they efficiently increase solubility. CDs are cyclic oligosaccharides with a hydrophilic outer surface and a hydrophobic inner cavity, enabling them to form inclusion complexes with poorly water-soluble drugs (<xref rid="polymers-17-00514-f001" ref-type="fig">Figure 1</xref>b). These complexes encapsulate hydrophobic molecules, protecting them from environmental degradation while significantly enhancing their solubility and stability [<xref rid="B8-polymers-17-00514" ref-type="bibr">8</xref>,<xref rid="B9-polymers-17-00514" ref-type="bibr">9</xref>]. Among CD derivatives, hydroxypropyl-&#x003b2;-cyclodextrin (HP-&#x003b2;-CD) is particularly advantageous due to its superior water solubility, low toxicity, and high complexation efficiency compared to native &#x003b2;-CD [<xref rid="B10-polymers-17-00514" ref-type="bibr">10</xref>,<xref rid="B11-polymers-17-00514" ref-type="bibr">11</xref>]. HP-&#x003b2;-CD has demonstrated efficacy in improving the solubility and stability of a range of drugs, including antifungal agents like ISN. This makes it an ideal candidate for addressing ISN&#x02019;s formulation challenges.</p><p>Vaginal in situ gelling systems present a promising platform for overcoming the limitations of traditional formulations [<xref rid="B5-polymers-17-00514" ref-type="bibr">5</xref>]. These systems are liquid at room temperature, enabling easy administration, but undergo a sol-to-gel transition upon exposure to physiological conditions such as body temperature or vaginal pH [<xref rid="B12-polymers-17-00514" ref-type="bibr">12</xref>,<xref rid="B13-polymers-17-00514" ref-type="bibr">13</xref>]. This transformation enhances mucoadhesive properties [<xref rid="B14-polymers-17-00514" ref-type="bibr">14</xref>], prolongs the residence time of the formulation in the vaginal cavity, and allows for sustained drug release. Such systems have been successfully utilized for a variety of therapeutic agents, including estriol and meloxicam, demonstrating improved efficacy and patient compliance [<xref rid="B15-polymers-17-00514" ref-type="bibr">15</xref>,<xref rid="B16-polymers-17-00514" ref-type="bibr">16</xref>].</p><p>Despite advancements, several gaps remain in the development of vaginal drug delivery systems. Many current formulations still suffer from rapid drug clearance, inadequate retention, and poor solubility of active agents. Furthermore, while cyclodextrins have been widely studied, their integration into thermosensitive vaginal in situ gels remains underexplored [<xref rid="B17-polymers-17-00514" ref-type="bibr">17</xref>]. This study aimed to address these challenges by developing a thermosensitive, mucoadhesive in situ gel containing ISN/HP-&#x003b2;-CD inclusion complexes (<xref rid="polymers-17-00514-f001" ref-type="fig">Figure 1</xref>c). The objectives were to enhance ISN&#x02019;s solubility and stability, improve its retention time in the vaginal cavity, and evaluate the formulation&#x02019;s in vitro release, antimicrobial activity, and stability. By incorporating Pluronic<sup>&#x000ae;</sup> F127 as a thermosensitive polymer and hydroxypropyl methylcellulose (HPMC) as a mucoadhesive agent, this study provides a novel therapeutic strategy for the effective treatment of vaginal infections [<xref rid="B18-polymers-17-00514" ref-type="bibr">18</xref>].</p></sec><sec id="sec2-polymers-17-00514"><title>2. Materials and Methods</title><sec id="sec2dot1-polymers-17-00514"><title>2.1. Materials</title><p>Isoconazole nitrate (ISN; Deva Pharma, Istanbul, Turkey) and (2-Hydroxypropyl)-&#x003b2;-cyclodextrin (HP-&#x003b2;-CD; Sigma-Aldrich, Steinheim, Germany) were utilized in this study. Pluronic<sup>&#x000ae;</sup> F127 (Poloxamer) and hydroxypropyl methylcellulose (HPMC) were also obtained from Sigma-Aldrich, Steinheim, Germany. Ethanol (99.5%) and methanol, both from Sigma-Aldrich, Germany, were used as solvents. Benzalkonium chloride was sourced from Fluka, Buchs, Denmark. The solution was prepared and diluted using ultrapure water (Merck, Darmstadt, Germany).</p><p>The Simulated Vaginal Fluid (SVF) was prepared using sodium chloride, potassium chloride, calcium hydroxide, bovine serum albumin, lactic acid, acetic acid, glucose, urea, glycerin, and distilled water, all sourced from Merck, Darmstadt, Germany, except glycerin, which was obtained from Do&#x0011f;a Pharma, Istanbul, Turkey.</p><p><italic toggle="yes">Candida albicans</italic> (ATCC 90028), <italic toggle="yes">Candida glabrata</italic> (ATCC 90030), and <italic toggle="yes">Candida krusei</italic> (ATCC 6258) were grown in Sabouraud dextrose broth and cultured on Mueller-Hinton agar and Sabouraud dextrose agar, all supplied by Merck, Darmstadt, Germany. All chemicals and reagents used were of analytical grade and sourced from their respective suppliers.</p></sec><sec id="sec2dot2-polymers-17-00514"><title>2.2. HPLC Method Development and Validation</title><p>The HPLC system (Shimadzu 20-A, Shimadzu Corporation, Kyoto, Japan) consisted of a diode array detector, an autosampler, an interface, and a pump. A VDSpher 100 C18-E reversed-phase column (VDS optilab, Berlin, Germany) (250 &#x000d7; 4.6 mm, 5 &#x003bc;m) was used for analysis. The mobile phase was a 50:50 (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) mixture of methanol and potassium dihydrogen phosphate buffer. Samples were analyzed at a flow rate of 0.5 mL/min and monitored at a wavelength of 210 nm. The temperature of the column oven was maintained at 40 &#x000b0;C, and the injection volume was set at 20 &#x003bc;L. Each experiment was performed in triplicate to ensure accuracy and reliability.</p></sec><sec id="sec2dot3-polymers-17-00514"><title>2.3. Preparation of ISN/HP-&#x003b2;-CD Complex</title><p>A specified amount of ISN was dissolved in methanol, while HP-&#x003b2;-CD was dissolved in water, maintaining a 1:1 molar ratio. The two clear solutions were mixed using a magnetic stirrer to ensure homogeneity. The resulting mixture was dried using a spray dryer equipped with a 0.7 mm diameter spray head. The feed rate was set at 7 mL/min with an outlet temperature of 60 &#x000b0;C and a feed temperature of 100 &#x000b0;C. The drying process produced fine powder complexes, which were collected in the designated container for further analysis [<xref rid="B19-polymers-17-00514" ref-type="bibr">19</xref>].</p></sec><sec id="sec2dot4-polymers-17-00514"><title>2.4. Structural and Physicochemical Characterization of ISN/HP-&#x003b2;-CD Complex</title><sec id="sec2dot4dot1-polymers-17-00514"><title>2.4.1. Phase-Solubility Profile and Complexation Efficiency</title><p>An aqueous solution containing HP-&#x003b2;-CD in concentrations ranging from 2 &#x000d7; 10<sup>&#x02212;3</sup> to 20 &#x000d7; 10<sup>&#x02212;3</sup> M was prepared. Excessive ISN (20 mg) was added in a 3:1 ratio to a mixture of the prepared CD solution and ethanol. The mixture was shaken on a horizontal shaker at 25 &#x000b0;C to produce supersaturated solutions, which were allowed to reach equilibrium over 24 h. After equilibration, the solutions were filtered through a nylon filter (0.45 &#x003bc;m) and analyzed by HPLC. The resulting data, obtained from three independent experiments, were used to construct a phase solubility diagram. The type of diagram was classified according to the Higuchi phase solubility model [<xref rid="B20-polymers-17-00514" ref-type="bibr">20</xref>].</p></sec><sec id="sec2dot4dot2-polymers-17-00514"><title>2.4.2. Physicochemical Characterization Tests of ISN/HP-&#x00392;-CD Inclusion Complex</title><p>ISN/HP-&#x003b2;-CD inclusion complexes were thoroughly characterized in vitro through investigations employing scanning electron microscopy (SEM), Fourier transform-infrared spectroscopy (FT-IR), proton nuclear magnetic resonance (<sup>1</sup>H-NMR), and differential scanning calorimetry (DSC). These measurements were performed for ISN, HP-&#x003b2;-CD, the physical mixture (ISN/HP-&#x003b2;-CD PM), and the ISN/HP-&#x003b2;-CD inclusion complex.</p><p>Differential scanning calorimetry (DSC; Shimadzu DSC-60, Shimadzu Corporation, Kyoto, Japan) was used to analyze the thermal behavior of the samples. Approximately 4 mg of each sample was sealed in aluminum pans, and the analysis was performed at a heating rate of 10 &#x000b0;C/min over a temperature range of 50&#x02013;400 &#x000b0;C. Thermograms were recorded to evaluate the thermal properties.</p><p>Proton nuclear magnetic resonance (<sup>1</sup>H-NMR; Bruker, Bruker Corporation, Billerica, MA, USA) spectra were obtained for all samples using deuterated dimethyl sulfoxide (DMSO-d<sub>6</sub>) as a solvent to investigate the molecular interactions between the components.</p><p>Fourier transform-infrared spectroscopy (FT-IR; Shimadzu, Shimadzu Corporation, Kyoto, Japan) was employed to investigate the samples. Spectra were recorded in the range of 500&#x02013;4000 cm<sup>&#x02212;1</sup> to identify functional group interactions and confirm complexation.</p><p>Scanning electron microscopy (SEM; Zeiss, Carl Zeiss AG, Oberkochen, Germany) was used to examine the surface morphology of the samples. The SEM images were analyzed to observe surface characteristics and structural differences.</p></sec></sec><sec id="sec2dot5-polymers-17-00514"><title>2.5. Preparation of In Situ Gel Systems</title><p>In situ gel systems were prepared using a cold method to prevent gelling during the formulation process due to heat exposure. Pluronic<sup>&#x000ae;</sup> F127 was the primary polymer used, and hydroxypropyl methylcellulose (HPMC) was incorporated into some formulations to evaluate its effect on the physicochemical properties of the gels.</p><p>The required amounts of Pluronic<sup>&#x000ae;</sup> F127, HPMC, and benzalkonium chloride were accurately weighed and added to a beaker containing sufficient distilled water. The mixture was stirred continuously with a magnetic stirrer (2 mm diameter bar) at 500 rpm for 24 h at approximately 4 &#x000b0;C. To maintain a consistent low temperature, fresh ice molds were added to the setup every four hours.</p><p>The composition and codes of the prepared formulations are summarized in <xref rid="polymers-17-00514-t001" ref-type="table">Table 1</xref>. This approach ensured uniform mixing and avoided premature gelation, resulting in stable formulations ready for further evaluation.</p></sec><sec id="sec2dot6-polymers-17-00514"><title>2.6. Physicochemical and Rheological Evaluation of In Situ Gel Formulations</title><p>The in situ gel formulations were evaluated for several parameters, including pH, gelation temperature, gelling capacity, swelling behavior, rheological properties, drug content (%), and antimicrobial efficacy. These characterizations were performed to ensure that the formulations met the desired performance criteria.</p><sec id="sec2dot6dot1-polymers-17-00514"><title>2.6.1. pH Measurement</title><p>The pH of the prepared formulations was determined using a pH meter (Mettler Toledo, Mettler-Toledo International Inc., Columbus, OH, USA). Each measurement was performed in triplicate to ensure accuracy and reproducibility.</p></sec><sec id="sec2dot6dot2-polymers-17-00514"><title>2.6.2. Gelation Behavior and Stability</title><p>The gelling capacity of the formulations was evaluated by adding a drop of the formulation into a vial containing 2 mL of SVF at 37 &#x000b0;C. The gelation process was observed visually, considering both the gelation time and the duration of gel stability. The results were recorded and interpreted using the coding system outlined in <xref rid="polymers-17-00514-t002" ref-type="table">Table 2</xref>, which categorizes the gelling behavior based on gelation and dissolution times [<xref rid="B21-polymers-17-00514" ref-type="bibr">21</xref>].</p></sec><sec id="sec2dot6dot3-polymers-17-00514"><title>2.6.3. Swelling Behavior Assessment</title><p>To evaluate the swelling behavior of the in situ gel formulations, 1 mL of each formulation was placed in a dialysis membrane, sealed using a dialysis membrane sealer, and immersed in Simulated Vaginal Fluid (SVF) at 37 &#x000b0;C. After a predefined incubation period, the swollen gel was carefully removed, and excess surface fluid was gently blotted using filter paper. The mass of the swollen gel (<inline-formula><mml:math id="mm1" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>s</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>) was then recorded.</p><p>To determine the mass of the dried gel (<inline-formula><mml:math id="mm2" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>d</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula>), the samples were left to dry completely under controlled conditions. The swelling percentage (<inline-formula><mml:math id="mm3" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>P</mml:mi></mml:mrow></mml:mrow></mml:math></inline-formula>) was calculated using the following equation [<xref rid="B22-polymers-17-00514" ref-type="bibr">22</xref>]:</p><p><disp-formula id="FD1-polymers-17-00514"><label>(1)</label><mml:math id="mm147" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mfenced><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mo>&#x000a0;</mml:mo><mml:msub><mml:mi>m</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>m</mml:mi><mml:mi>d</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mrow><mml:mi>d</mml:mi><mml:mo>&#x000a0;</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mfenced><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
where <italic toggle="yes">m<sub>s</sub></italic> is the mass of swelled gel, <italic toggle="yes">m<sub>d</sub></italic> is the mass of dried gel.</p></sec><sec id="sec2dot6dot4-polymers-17-00514"><title>2.6.4. Rheological and Viscosity Analysis</title><p>The rheological properties of the formulations were evaluated using a rheometer (Brookfield, AMETEK Brookfield, Middleboro, MA, USA) at two different temperatures: 25 &#x000b0;C and 37 &#x000b0;C. Changes in shear stress and viscosity versus shear rate were recorded to evaluate the flow behavior of the formulations at both temperatures.</p></sec><sec id="sec2dot6dot5-polymers-17-00514"><title>2.6.5. Drug Content Analysis</title><p>To determine the drug content (DC%) of ISN in the formulations, 100 mg of the prepared gel was dissolved in 1 mL of 50% methanol. The solution was then diluted to the required concentration with the same solvent and analyzed using a validated HPLC method.</p></sec><sec id="sec2dot6dot6-polymers-17-00514"><title>2.6.6. In Vitro Release Studies of In Situ Gel Formulations</title><p>A specific amount of the in situ gel formulation was carefully loaded into a dialysis bag, which was sealed and included a magnetic stirring bar to ensure consistent agitation during the in vitro release study, mimicking physiological conditions. The sealed dialysis bag was placed in a beaker containing 50 mL of SVF with a pH of 4.5 as the release medium. The experiment was performed at 37 &#x000b1; 0.5 &#x000b0;C using a magnetic stirrer set to 100 rpm. At predetermined time intervals (0.25, 0.5, 1, 2, 3, 4, 6, 9, 12, 24, 48, 72, and 96 h), 1 mL samples were taken from the receptor medium and replaced with an equal volume of fresh SVF to maintain sink conditions. The collected samples were analyzed using a validated HPLC method. Drug release kinetics were evaluated using the DD Solver program to determine the release mechanism from the in situ gel systems.</p></sec><sec id="sec2dot6dot7-polymers-17-00514"><title>2.6.7. Antifungal Activity Against Candida Strains</title><p>Antimicrobial activity was assessed against <italic toggle="yes">Candida albicans</italic> (<italic toggle="yes">C. albicans</italic>, ATCC 90028), <italic toggle="yes">Candida glabrata</italic> (<italic toggle="yes">C. glabrata</italic>, ATCC 90030), and <italic toggle="yes">Candida krusei</italic> (<italic toggle="yes">C. krusei</italic>, ATCC 6258). The agar diffusion method, a widely used technique for evaluating microorganism sensitivity, was used. Petri dishes (90 mm diameter) were filled with 20&#x02013;25 mL of Sabouraud dextrose agar under aseptic conditions and allowed to solidify. Then, 100 &#x003bc;L of yeast suspension, adjusted spectrophotometrically at 530 nm to match turbidity equivalent to 0.5 McFarland standard, was spread evenly over the agar surface.</p><p>Once the surface dried completely (approximately 10 min at 25 &#x000b0;C), 6 mm wells were created in the agar using a sterile cork borer. Each well was filled with 35 &#x003bc;L of the test formulation containing ISN at a concentration of 3 &#x003bc;g/mL. Plates were incubated at 37 &#x000b0;C for 24 h to allow for microbial growth and diffusion of the formulations. Zones of inhibition around the wells were measured to determine the antimicrobial efficacy of the in situ gel formulations.</p></sec></sec></sec><sec sec-type="results" id="sec3-polymers-17-00514"><title>3. Results</title><sec id="sec3dot1-polymers-17-00514"><title>3.1. Validation of HPLC Method for ISN Quantification</title><p>A calibration curve for ISN was prepared using the mobile phase as the diluent. The HPLC method, operating at a wavelength of 210 nm, exhibited excellent linearity across the concentration range of 20&#x02013;500 &#x003bc;g/mL, with a correlation coefficient (r<sup>2</sup>) of 0.9998. The method was further validated, demonstrating that it meets all necessary criteria for alternative validation parameters. <xref rid="polymers-17-00514-f002" ref-type="fig">Figure 2</xref> shows the calibration curve and the linearity equation for the ISN standard.</p></sec><sec id="sec3dot2-polymers-17-00514"><title>3.2. Structural and Physicochemical Characterization of ISN/HP-&#x003b2;-CD Complex</title><sec id="sec3dot2dot1-polymers-17-00514"><title>3.2.1. Phase-Solubility Profile and Complexation Efficiency</title><p>Phase solubility studies provide essential information regarding the stability constant, complexation stoichiometry, and solubility enhancement of drug&#x02013;CD inclusion complexes [<xref rid="B11-polymers-17-00514" ref-type="bibr">11</xref>]. This method is widely used to evaluate how drug&#x02013;CD complexation influences the solubility of poorly soluble drugs. Among the different inclusion types, the most common stoichiometry is a 1:1 drug&#x02013;CD complex, where the stability constant (K1:1) quantifies the equilibrium between free and complexed species.</p><p>The phase solubility plot (<xref rid="polymers-17-00514-f003" ref-type="fig">Figure 3</xref>) showed that the solubility of ISN increased proportionally with the concentration of HP-&#x003b2;-CD, confirming the formation of inclusion complexes. The plot was classified as &#x0201c;AL-type&#x0201d;, with a slope of 0.5032 and a strong correlation coefficient (R2 = 0.9897). The stability constant (Ks) for the ISN/HP-&#x003b2;-CD complex was calculated to be 803.52 M<sup>&#x02212;1</sup>, which is within the acceptable range of 100&#x02013;10,000 M<sup>&#x02212;1</sup>, as reported in the literature, indicating stable complexation [<xref rid="B23-polymers-17-00514" ref-type="bibr">23</xref>].</p></sec><sec id="sec3dot2dot2-polymers-17-00514"><title>3.2.2. Solubility of ISN/HP-&#x003b2;-CD Inclusion Complex</title><p>To evaluate the solubility enhancement achieved by complexation, saturated solutions of ISN and ISN/HP-&#x003b2;-CD were prepared, and their water solubility was analyzed. ISN, known for its poor water solubility, was found to have a solubility of approximately 0.5088 mg/mL. However, upon forming the inclusion complex with HP-&#x003b2;-CD, the solubility increased significantly to 3.6550 mg/mL, resulting in a clear solution. This demonstrates the effectiveness of the HP-&#x003b2;-CD complexation approach in improving the solubility of ISN and achieving a more soluble formulation.</p></sec><sec id="sec3dot2dot3-polymers-17-00514"><title>3.2.3. Morphological Studies of ISN/HP-&#x003b2;-CD Inclusion Complex</title><p>The surface morphology of ISN, HP-&#x003b2;-CD, their physical mixture (PM), and the ISN/HP-&#x003b2;-CD inclusion complex was analyzed using scanning electron microscopy. <xref rid="polymers-17-00514-f004" ref-type="fig">Figure 4</xref> presents the SEM images of (a) pure ISN, (b) pure HP-&#x003b2;-CD, (c) the physical mixture of ISN and HP-&#x003b2;-CD, and (d) the ISN/HP-&#x003b2;-CD inclusion complex.</p><p>Pure ISN (<xref rid="polymers-17-00514-f004" ref-type="fig">Figure 4</xref>a) exhibited irregularly shaped particles with a semi-crystalline structure, characterized by a rough surface and uneven particle sizes. HP-&#x003b2;-CD (<xref rid="polymers-17-00514-f004" ref-type="fig">Figure 4</xref>b) displayed a spherical morphology with characteristic cavities, indicative of its porous molecular structure. The physical mixture (PM) of ISN and HP-&#x003b2;-CD (<xref rid="polymers-17-00514-f004" ref-type="fig">Figure 4</xref>c) displayed a combination of the morphologies of the individual components, indicating no significant interaction between the drug and cyclodextrin molecules in this state.</p><p>In contrast, the ISN/HP-&#x003b2;-CD inclusion complex (<xref rid="polymers-17-00514-f004" ref-type="fig">Figure 4</xref>d) exhibited a distinct transformation compared to its individual components. The particles appeared chaotic and somewhat spherical, with the disappearance of the crystalline structure of ISN and the porous cavities of HP-&#x003b2;-CD. These pronounced morphological changes can be attributed to the successful formation of the inclusion complex, where ISN is encapsulated within the hydrophobic cavity of HP-&#x003b2;-CD. This encapsulation results in molecular rearrangement and an amorphous appearance, supporting the enhanced solubility and stability of ISN within the HP-&#x003b2;-CD matrix.</p></sec><sec id="sec3dot2dot4-polymers-17-00514"><title>3.2.4. Thermal Analysis of ISN/HP-&#x003b2;-CD Inclusion Complex</title><p>Differential Scanning Calorimetry (DSC) is an essential technique for investigating the thermal properties and phase behavior of drug-polymer systems [<xref rid="B24-polymers-17-00514" ref-type="bibr">24</xref>,<xref rid="B25-polymers-17-00514" ref-type="bibr">25</xref>]. The DSC thermograms of pure ISN, HP-&#x003b2;-CD, ISN/HP-&#x003b2;-CD physical mixture (PM), and ISN/HP-&#x003b2;-CD inclusion complex are presented in <xref rid="polymers-17-00514-f005" ref-type="fig">Figure 5</xref>. The thermogram of pure ISN exhibited a sharp endothermic peak at 187.5 &#x000b0;C, indicative of its crystalline nature. In contrast, HP-&#x003b2;-CD displayed two broad endothermic peaks: one at ~80 &#x000b0;C, corresponding to the loss of bound water molecules, and another at ~270 &#x000b0;C, associated with its thermal degradation, confirming its amorphous nature.</p><p>The physical mixture retained both the ISN melting peak and the dehydration peak of HP-&#x003b2;-CD, though the ISN peak was slightly broader and shifted. This suggests minor interactions but no significant complex formation, indicating that simple mixing does not induce strong molecular interactions. However, the DSC thermogram of the ISN/HP-&#x003b2;-CD inclusion complex showed a complete disappearance of the ISN melting peak, suggesting successful encapsulation of ISN within the HP-&#x003b2;-CD cavity and a transition from a crystalline to an amorphous state [<xref rid="B26-polymers-17-00514" ref-type="bibr">26</xref>,<xref rid="B27-polymers-17-00514" ref-type="bibr">27</xref>]. This structural transformation is advantageous for improving solubility and bioavailability, as amorphous forms typically exhibit enhanced dissolution properties.</p><p>The DSC results confirm that the ISN/HP-&#x003b2;-CD inclusion complex has a distinct thermal profile, characterized by the absence of the ISN melting peak and the presence of broad thermal events associated with HP-&#x003b2;-CD. These findings indicate strong molecular interactions between ISN and HP-&#x003b2;-CD, supporting the successful formation of the inclusion complex. This transformation enhances the thermal stability and pharmaceutical performance of ISN, making the complex a promising formulation for improved drug solubility and bioavailability.</p></sec><sec id="sec3dot2dot5-polymers-17-00514"><title>3.2.5. FT-IR Analysis of ISN/HP-&#x003b2;-CD Inclusion Complex</title><p>FT-IR spectroscopy was conducted to investigate the molecular interactions between Isoconazole Nitrate (ISN) and Hydroxypropyl-&#x003b2;-Cyclodextrin (HP-&#x003b2;-CD) by comparing the spectra of pure ISN, HP-&#x003b2;-CD, their physical mixture (PM), and the inclusion complex (<xref rid="polymers-17-00514-f006" ref-type="fig">Figure 6</xref>). Key functional groups were identified based on characteristic absorption bands.</p><p>The FT-IR spectrum of ISN displayed a broad peak at 3059 cm<sup>&#x02212;1</sup>, corresponding to aromatic C-H stretching, along with a peak at 2617 cm<sup>&#x02212;1</sup>, which may be an overtone or combination band. The absorption at 1585 cm<sup>&#x02212;1</sup> was attributed to C=C stretching in the aromatic rings, while the bands at 1449 cm<sup>&#x02212;1</sup> and 1382 cm<sup>&#x02212;1</sup> were associated with NO<sub>3</sub><sup>&#x02212;</sup> asymmetric and symmetric stretching, confirming the presence of the nitrate functionality [<xref rid="B28-polymers-17-00514" ref-type="bibr">28</xref>,<xref rid="B29-polymers-17-00514" ref-type="bibr">29</xref>]. Additional peaks at 1094 cm<sup>&#x02212;1</sup> corresponded to C-O-C stretching, while those at 870 cm<sup>&#x02212;1</sup> and 760 cm<sup>&#x02212;1</sup> were attributed to C-Cl stretching, indicating the presence of ether and chlorinated aromatic groups. These findings align with previous reports on Isoconazole, as obtained by Drabi&#x00144;ska et al. [<xref rid="B30-polymers-17-00514" ref-type="bibr">30</xref>].</p><p>The FT-IR spectrum of HP-&#x003b2;-CD exhibited a characteristic broad band at 3345 cm<sup>&#x02212;1</sup>, corresponding to O-H stretching, indicative of an extensive hydrogen bonding network. The peaks at 2911 cm<sup>&#x02212;1</sup> represented C-H stretching, while the absorption at 1636 cm<sup>&#x02212;1</sup> was attributed to H-O-H bending, signifying the presence of water molecules. The absorption bands at 1150 cm<sup>&#x02212;1</sup> and 1024 cm<sup>&#x02212;1</sup> corresponded to C-O stretching and C-O-C stretching, respectively, characteristic of the ether bonds in the glycosidic structure. Peaks at 947 cm<sup>&#x02212;1</sup> and 847 cm<sup>&#x02212;1</sup> were associated with ring vibrations and glycosidic linkage vibrations, confirming the presence of glucopyranose units. These results are consistent with those reported in the literature [<xref rid="B31-polymers-17-00514" ref-type="bibr">31</xref>,<xref rid="B32-polymers-17-00514" ref-type="bibr">32</xref>,<xref rid="B33-polymers-17-00514" ref-type="bibr">33</xref>].</p><p>The FT-IR spectrum of the physical mixture (PM) revealed an overlay of peaks from both ISN and HP-&#x003b2;-CD, indicating their coexistence without significant molecular interactions (<xref rid="polymers-17-00514-f006" ref-type="fig">Figure 6</xref>c). The peak at 2904 cm<sup>&#x02212;1</sup> was assigned to C-H stretching, while the absorption at 2351 cm<sup>&#x02212;1</sup> likely corresponded to atmospheric CO<sub>2</sub> absorption or overtone vibrations. The NO<sub>3</sub><sup>&#x02212;</sup> symmetric and asymmetric stretching bands appeared at 1385 cm<sup>&#x02212;1</sup> and 1339 cm<sup>&#x02212;1</sup>, confirming the presence of ISN. The C-O-C stretching vibrations of HP-&#x003b2;-CD were observed at 1153 cm<sup>&#x02212;1</sup> and 1026 cm<sup>&#x02212;1</sup>, while the C-Cl stretching vibrations from ISN appeared at 880.25 cm<sup>&#x02212;1</sup> and 760 cm<sup>&#x02212;1</sup>. Additionally, the peak at 640 cm<sup>&#x02212;1</sup> was associated with out-of-plane bending vibrations. The preservation of these distinct peaks without significant shifts or intensity changes suggests that only physical mixing occurred, with ISN retaining its molecular integrity and HP-&#x003b2;-CD remaining structurally unmodified.</p><p>The FT-IR spectrum of the inclusion complex (<xref rid="polymers-17-00514-f006" ref-type="fig">Figure 6</xref>d) demonstrated key changes indicative of successful complexation between ISN and HP-&#x003b2;-CD. The NO<sub>3</sub><sup>&#x02212;</sup> symmetric stretching band at 1394 cm<sup>&#x02212;1</sup> was weakened, suggesting an interaction between the nitrate group of ISN and the cyclodextrin cavity. Additionally, the C-Cl stretching peaks from ISN (949 cm<sup>&#x02212;1</sup>, 863 cm<sup>&#x02212;1</sup>, and 768 cm<sup>&#x02212;1</sup>) showed reduced intensity, further supporting ISN&#x02019;s encapsulation within HP-&#x003b2;-CD. The C-O-C stretching bands of HP-&#x003b2;-CD at 1154 cm<sup>&#x02212;1</sup> and 1028 cm<sup>&#x02212;1</sup> remained intact, confirming the structural preservation of the cyclodextrin. These spectral shifts, along with the disappearance of ISN-specific peaks, confirm the formation of the inclusion complex, which enhances ISN&#x02019;s solubility and stability, making it a promising formulation for improving its pharmaceutical properties. The observed changes are consistent with established literature on host-guest interactions in cyclodextrin complexes [<xref rid="B34-polymers-17-00514" ref-type="bibr">34</xref>].</p></sec><sec id="sec3dot2dot6-polymers-17-00514"><title>3.2.6. <sup>1</sup>H-NMR Analysis of ISN/HP-&#x003b2;-CD Inclusion Complex</title><p>The <sup>1</sup>H NMR spectra of ISN, HP-&#x003b2;-CD, their physical mixture (PM), and the inclusion complex (ISN/HP-&#x003b2;-CD) provide critical insights into the molecular interactions between ISN and HP-&#x003b2;-CD. A comparative analysis of chemical shifts (&#x003b4;), peak intensities, and the disappearance or broadening of specific signals confirms the formation of an inclusion complex (<xref rid="polymers-17-00514-f007" ref-type="fig">Figure 7</xref>).</p><p>The <sup>1</sup>H NMR spectrum of ISN presents well-defined peaks, with aromatic protons (Ar-H) appearing in the 7.3&#x02013;9.0 ppm range, corresponding to the benzene and imidazole rings. The benzylic methylene (-CH<sub>2</sub>-) protons adjacent to the oxygen atom appear between 5.10 and 5.70 ppm, while ether (-OCH<sub>2</sub>-) protons resonate in the 3.1&#x02013;4.5 ppm region. The solvent signal from DMSO-d<sub>6</sub> is visible at 2.50 ppm, with a residual water peak around 3.3 ppm. These signals confirm the structural integrity of ISN (<xref rid="polymers-17-00514-f007" ref-type="fig">Figure 7</xref>a).</p><p>HP-&#x003b2;-CD exhibits characteristic glucose ring proton signals, with chemical shifts for H-1, H-2, H-3, H-4, H-5, and H-6 at 4.985, 3.520, 3.969, 3.418, 3.762, and 3.867 ppm, respectively. These values match previously reported data for HP-&#x003b2;-CD and indicate a well-preserved cyclodextrin structure (<xref rid="polymers-17-00514-f007" ref-type="fig">Figure 7</xref>b) [<xref rid="B35-polymers-17-00514" ref-type="bibr">35</xref>,<xref rid="B36-polymers-17-00514" ref-type="bibr">36</xref>]. The importance of H-3 and H-5 lies in their involvement in host-guest interactions, making them key binding sites in inclusion complexes [<xref rid="B37-polymers-17-00514" ref-type="bibr">37</xref>,<xref rid="B38-polymers-17-00514" ref-type="bibr">38</xref>]. The absence of additional peaks confirms the purity and stability of HP-&#x003b2;-CD in DMSO-d<sub>6</sub>.</p><p>The <sup>1</sup>H NMR spectrum of the physical mixture of ISN and HP-&#x003b2;-CD contains peaks from both individual components, confirming the presence of unbound ISN and HP-&#x003b2;-CD in the mixture (<xref rid="polymers-17-00514-f007" ref-type="fig">Figure 7</xref>c). The ISN peaks remain prominent, and no significant chemical shift changes are observed in HP-&#x003b2;-CD protons. This indicates that there is no strong interaction or inclusion occurring between ISN and HP-&#x003b2;-CD in the physical mixture. Only minor intensity variations are noticed, which are likely due to dilution effects and intermolecular interactions rather than true complexation.</p><p>In contrast to the PM, the <sup>1</sup>H NMR spectrum of the inclusion complex reveals significant spectral changes (<xref rid="polymers-17-00514-f007" ref-type="fig">Figure 7</xref>d). The ISN peaks appear broadened or reduced in intensity, indicating encapsulation inside the HP-&#x003b2;-CD cavity. This is attributed to molecular shielding effects caused by host-guest interactions. The most notable chemical shift changes occur at H-3 and H-5, shifting from 3.969 ppm to 3.9655 ppm and 3.762 ppm to 3.7595 ppm, respectively. These changes, reflected in &#x00394;&#x003b4;<sub>1</sub> values, confirm that the interaction is localized at these specific binding sites.</p><p><xref rid="polymers-17-00514-t003" ref-type="table">Table 3</xref> presents the chemical shift differences (&#x00394;&#x003b4;<sub>1</sub> and &#x00394;&#x003b4;<sub>2</sub>) for HP-&#x003b2;-CD in the PM and complex. The largest shifts at H-3 (&#x02212;0.0035 ppm) and H-5 (&#x02212;0.0025 ppm) confirm that these protons participate in the binding interaction with ISN. Conversely, H-1, H-2, H-4, and H-6 exhibit negligible changes, reinforcing that the inclusion occurs selectively at H-3 and H-5. The PM spectrum lacks these shifts, further proving that true complexation only occurs in the inclusion system.</p><p>The <sup>1</sup>H NMR analysis suggests the formation of the ISN/HP-&#x003b2;-CD inclusion complex. The selective chemical shift changes at H-3 and H-5 and the reduced intensities of ISN peaks indicate molecular encapsulation. Since no significant changes occur in the PM, the findings support that ISN interacts specifically with HP-&#x003b2;-CD through host-guest interactions, aligning with previously reported cyclodextrin inclusion complexes.</p></sec></sec><sec id="sec3dot3-polymers-17-00514"><title>3.3. In Situ Gel Evaluation: Rheology, pH, and Drug Content</title><sec id="sec3dot3dot1-polymers-17-00514"><title>3.3.1. pH Measurement and Gelation Temperature</title><p>The pH values and gelation temperatures of the formulated in situ gels were evaluated to determine their suitability for vaginal application (<xref rid="polymers-17-00514-t004" ref-type="table">Table 4</xref>). The most promising formulations were F12.75H05, which gelled at 33 &#x000b0;C with a pH of 4.04; F14, which gelled at 26 &#x000b0;C with a pH of 4.50; C13.5H05-HP&#x003b2;CD, which gelled at 30 &#x000b0;C with a pH of 4.86; and C14 HP&#x003b2;CD, which gelled at 30 &#x000b0;C with a pH of 4.37. These formulations demonstrated favorable gelation properties, making them strong candidates for vaginal drug delivery.</p><p>One of the critical factors affecting the biocompatibility of vaginal formulations is pH, as it plays a significant role in maintaining vaginal homeostasis. The normal vaginal pH typically falls between 3.5 and 4.5, helping to sustain the natural microbial flora and acting as a defense mechanism against infections. Vaginal formulations should align with this pH range to prevent irritation and maintain the physiological balance of the vaginal environment. Additionally, formulations with a compatible pH may help restore vaginal acidity, particularly in individuals experiencing bacterial vaginosis or postmenopausal vaginal atrophy, where pH imbalances can contribute to discomfort and increased susceptibility to infections.</p><p>All the tested formulations exhibited pH values within the acceptable vaginal range, indicating their potential suitability for vaginal application. The pH values of these formulations suggest they can be well-tolerated and safe for vaginal administration, ensuring patient comfort and therapeutic effectiveness [<xref rid="B39-polymers-17-00514" ref-type="bibr">39</xref>].</p></sec><sec id="sec3dot3dot2-polymers-17-00514"><title>3.3.2. Gelation Strength and Retention in Simulated Vaginal Fluid</title><p>The in situ gel formulations were designed to undergo gelation at 37 &#x000b0;C, ensuring prolonged retention at the application site and sustained drug release. Maintaining an optimal gel structure is essential, as formulations that dissolve too quickly may lead to rapid drug depletion, while highly viscous gels may hinder effective drug diffusion.</p><p>The formulations demonstrated rapid gelation at 37 &#x000b0;C with sufficient strength to sustain controlled drug release. As shown in <xref rid="polymers-17-00514-t005" ref-type="table">Table 5</xref>, all formulations exhibited a gelling capacity rating of (+++), confirming their stability and suitability for vaginal drug delivery.</p><p>These results confirm that the formulated in situ gels have the desired balance between gel strength and viscosity, ensuring effective retention and sustained drug release.</p></sec><sec id="sec3dot3dot3-polymers-17-00514"><title>3.3.3. Swelling Kinetics in Simulated Vaginal Conditions</title><p>The swelling behavior of the in situ gel formulations was evaluated over a 72 h period using dialysis membranes, which were sealed with a dialysis membrane sealer to maintain controlled conditions. The initial mass of the gel was recorded before the test. The results indicated a gradual increase in swelling over time, showing a proportionate and sustained absorption of fluid.</p><p>After 72 h, the swelling percentages were measured as 118.219% for F12.75H05, 184.837% for F14, 195.096% for C13.5H05HP&#x003b2;CD, and 142.156% for C14HP&#x003b2;CD, confirming the gels&#x02019; ability to absorb and retain fluid effectively.</p></sec><sec id="sec3dot3dot4-polymers-17-00514"><title>3.3.4. Measurement of the Rheological Properties</title><p>The rheological properties of in situ gel formulations play a crucial role in predicting their in vivo performance, particularly for vaginal drug delivery [<xref rid="B40-polymers-17-00514" ref-type="bibr">40</xref>]. <xref rid="polymers-17-00514-f008" ref-type="fig">Figure 8</xref> illustrates the rheograms of the formulations at 25 &#x000b0;C, while <xref rid="polymers-17-00514-f009" ref-type="fig">Figure 9</xref> shows their behavior at 37 &#x000b0;C, providing insight into their shear stress and viscosity profiles.</p><p>At 25 &#x000b0;C, the formulations exhibited a progressive increase in shear stress with increasing shear rate, indicating shear-thinning behavior (<xref rid="polymers-17-00514-f008" ref-type="fig">Figure 8</xref>). This response suggests that the gels remain easily spreadable at room temperature, facilitating their administration and uniform distribution upon application. The viscosity of the formulations decreased as the shear rate increased, which is characteristic of pseudoplastic (non-Newtonian) flow.</p><p>At 37 &#x000b0;C, all formulations demonstrated a transition to a gel phase, displaying non-Newtonian pseudoplastic behavior (<xref rid="polymers-17-00514-f009" ref-type="fig">Figure 9</xref>). This transformation is expected for Pluronic<sup>&#x000ae;</sup>-based thermosensitive drug delivery systems, where gelation occurs above the sol&#x02013;gel transition temperature [<xref rid="B41-polymers-17-00514" ref-type="bibr">41</xref>]. The increased viscosity at physiological temperature enhances residence time, ensuring sustained drug release at the application site.</p><p>Among the tested formulations, C13.5H05HP&#x003b2;CD exhibited the highest viscosity, followed by C14HP&#x003b2;CD, F12.75H05, and F14. The presence of HPMC contributed to increased mucoadhesion and formulation viscosity, which may improve retention within the vaginal mucosa [<xref rid="B39-polymers-17-00514" ref-type="bibr">39</xref>]. Additionally, it has been reported that HPMC-containing formulations exhibit higher elasticity values, further supporting prolonged retention and controlled drug release.</p><p>The rheological properties observed in these formulations are crucial for ensuring optimal application, spreadability, and prolonged drug residence time. The higher viscosity and gel strength of the HP&#x003b2;CD-containing formulations suggest their potential for enhanced bioavailability and prolonged therapeutic action.</p></sec><sec id="sec3dot3dot5-polymers-17-00514"><title>3.3.5. Determination of Drug Content (DC%)</title><p>The drug content of the in situ gel formulations was assessed to ensure uniform distribution and compliance with pharmaceutical standards. ISN and ISN/HP-&#x003b2;-CD inclusion complexes were incorporated into the gels at a 2% ratio, following industry guidelines for vaginal formulations.</p><p>The measured drug content values for the formulations are presented in <xref rid="polymers-17-00514-t006" ref-type="table">Table 6</xref>. The formulations containing pure ISN (F12.75H05 and F14) exhibited drug content values of 0.615% and 0.749%, respectively. Meanwhile, the ISN/HP-&#x003b2;-CD inclusion complex formulations (C13.5H05HP&#x003b2;CD and C14HP&#x003b2;CD) showed drug content values of 0.655% and 0.652%, respectively. Although slightly lower than the theoretical value, these results remain within acceptable pharmaceutical limits for formulation variability. The findings confirm uniform dispersion of the active ingredient within the gel matrices, supporting reproducibility and therapeutic effectiveness [<xref rid="B42-polymers-17-00514" ref-type="bibr">42</xref>].</p></sec><sec id="sec3dot3dot6-polymers-17-00514"><title>3.3.6. In Vitro Release Studies of In Situ Gel Formulations</title><p>The in vitro drug release study plays a critical role in optimizing pharmaceutical formulations. The release profiles of the in situ gel systems are presented in <xref rid="polymers-17-00514-f010" ref-type="fig">Figure 10</xref>. The results indicate that formulations containing ISN/HP-&#x003b2;-CD inclusion complexes (C13.5H05-HP&#x003b2;CD and C14-HP&#x003b2;CD) exhibited a higher drug release rate compared to formulations with pure ISN (F12.75H05 and F14). This enhancement is attributed to the improved water solubility of the inclusion complexes, which facilitates faster drug dissolution and diffusion.</p><p>In addition to higher solubility, the formulations incorporating inclusion complexes demonstrated a prolonged drug release profile, as illustrated in <xref rid="polymers-17-00514-f011" ref-type="fig">Figure 11</xref>. The ISN/HP-&#x003b2;-CD-loaded gels extended ISN release by approximately 1.5&#x02013;2 times compared to formulations with pure ISN. This suggests a potential reduction in dosage frequency, which can enhance patient compliance and overall treatment efficacy for antifungal therapy [<xref rid="B43-polymers-17-00514" ref-type="bibr">43</xref>].</p><p>To further understand the release mechanisms, DD-Solver software (version 1.0) was used to analyze the kinetics of drug release. The release data showed the best fit to the Peppas-Sahlin model, which describes a dual mechanism involving diffusion-controlled (Fickian) release and polymer relaxation-driven (non-Fickian) release. This indicates that the release of ISN from the in situ gel systems is primarily controlled by diffusion, influenced by polymer matrix relaxation [<xref rid="B44-polymers-17-00514" ref-type="bibr">44</xref>].</p></sec><sec id="sec3dot3dot7-polymers-17-00514"><title>3.3.7. Comparative Antifungal Efficacy Against Candida Strains</title><p>The antimicrobial efficacy of the formulated in situ gels was assessed by measuring the inhibition zone diameters after a 24 h incubation period. The study focused on evaluating the antifungal activity of pure ISN-loaded gels and ISN/HP-&#x003b2;-CD inclusion complex-loaded gels against <italic toggle="yes">Candida albicans</italic>, <italic toggle="yes">Candida glabrata</italic>, and <italic toggle="yes">Candida krusei</italic>.</p><p>The results, summarized in <xref rid="polymers-17-00514-t007" ref-type="table">Table 7</xref>, revealed that all tested formulations exhibited antifungal activity, with varying degrees of inhibition depending on the formulation and fungal strain. The highest inhibition zones against <italic toggle="yes">C. glabrata</italic> followed the sequence: C13.5H05HP&#x003b2;CD &#x0003e; F12.75H05 &#x0003e; C14HP&#x003b2;CD &#x0003e; F14. Similarly, the formulations with the most significant inhibition against C. krusei were ranked as C14HP&#x003b2;CD &#x0003e; C13.5H05HP&#x003b2;CD = F12.75H05 &#x0003e; F14. Against C. albicans, the order of effectiveness was observed as C13.5H05HP&#x003b2;CD &#x0003e; F12.75H05 &#x0003e; C14HP&#x003b2;CD &#x0003e; F14.</p><p>These results indicate that incorporating HP-&#x003b2;-CD into the formulation did not diminish ISN&#x02019;s antifungal efficacy; instead, it enhanced its performance against the tested fungal strains. Furthermore, placebo formulations (without ISN) did not exhibit any inhibition zones, confirming that the antifungal activity was solely attributed to ISN and its inclusion complex.</p></sec></sec></sec><sec sec-type="conclusions" id="sec4-polymers-17-00514"><title>4. Conclusions</title><p>This study successfully developed in situ gel formulations incorporating isoconazole nitrate (ISN) and its inclusion complex with hydroxypropyl-&#x003b2;-cyclodextrin (HP-&#x003b2;-CD) to enhance solubility, stability, and antifungal efficacy for vaginal drug delivery. The spray-dried inclusion complexes significantly improved the aqueous solubility of ISN, which contributed to its enhanced dissolution and bioavailability. The optimized thermosensitive, mucoadhesive in situ gel formulations, prepared using Pluronic<sup>&#x000ae;</sup> F127 and hydroxypropyl methylcellulose (HPMC), demonstrated ideal gelation properties, ensuring prolonged retention at the site of action.</p><p>The physicochemical characterization confirmed the successful formation of the ISN/HP-&#x003b2;-CD inclusion complex, as evidenced by FT-IR, DSC, SEM, and <sup>1</sup>H-NMR analyses. The rheological studies further validated the formulations&#x02019; pseudoplastic behavior, ensuring ease of application and stability under physiological conditions. Additionally, in vitro release studies indicated a sustained drug release profile, following the Peppas-Sahlin model, suggesting a combined diffusion and relaxation-controlled mechanism.</p><p>Most importantly, antimicrobial testing demonstrated superior antifungal efficacy of the ISN:HP-&#x003b2;-CD-loaded gels against <italic toggle="yes">Candida albicans</italic>, <italic toggle="yes">Candida glabrata</italic>, and <italic toggle="yes">Candida krusei</italic>, surpassing the activity of pure ISN formulations. This highlights the potential of cyclodextrin complexation in enhancing drug solubility and therapeutic effectiveness.</p><p>Overall, this study provides a promising novel approach for vaginal drug delivery, leveraging cyclodextrin-based inclusion complexation and mucoadhesive in situ gelling systems to optimize ISN&#x02019;s antifungal activity. These findings pave the way for further clinical evaluation, ensuring a patient-friendly, effective, and long-acting treatment for vaginal infections.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, T.A. and G.Y.K.; methodology, T.A. and G.Y.K.; software, T.A. and G.Y.K.; investigation, T.A. and G.Y.K.; data curation, T.A. and G.Y.K.; formal analysis, T.A.; writing&#x02014;original draft preparation, T.A. and G.Y.K.; writing&#x02014;review and editing, T.A. and G.Y.K. All the authors discussed the results and commented on the manuscript. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available in this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><glossary><title>Abbreviations</title><p>The abbreviations used in this manuscript are as follows:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ISN</td><td align="left" valign="middle" rowspan="1" colspan="1">Isoconazole Nitrate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HP-&#x003b2;-CD</td><td align="left" valign="middle" rowspan="1" colspan="1">Hydroxypropyl-&#x003b2;-cyclodextrin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SEM</td><td align="left" valign="middle" rowspan="1" colspan="1">Scanning Electron Microscopy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FT-IR</td><td align="left" valign="middle" rowspan="1" colspan="1">Fourier Transform Infrared Spectroscopy</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1"><sup>1</sup>H-NMR</td><td align="left" valign="middle" rowspan="1" colspan="1">Proton Nuclear Magnetic Resonance</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DSC</td><td align="left" valign="middle" rowspan="1" colspan="1">Differential Scanning Calorimetry</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HPMC</td><td align="left" valign="middle" rowspan="1" colspan="1">Hydroxypropyl Methylcellulose</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CDs</td><td align="left" valign="middle" rowspan="1" colspan="1">Cyclodextrins</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SVF</td><td align="left" valign="middle" rowspan="1" colspan="1">Simulated Vaginal Fluid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HPLC</td><td align="left" valign="middle" rowspan="1" colspan="1">High-Performance Liquid Chromatography</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PM</td><td align="left" valign="middle" rowspan="1" colspan="1">Physical Mixture</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DMSO-d<sub>6</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">Deuterated Dimethyl Sulfoxide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">rpm</td><td align="left" valign="middle" rowspan="1" colspan="1">Revolutions Per Minute</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DC%</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug Content Percentage</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DD Solver</td><td align="left" valign="middle" rowspan="1" colspan="1">Drug Dissolution Solver Program</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">K1:1</td><td align="left" valign="middle" rowspan="1" colspan="1">Stability Constant for 1:1 Drug&#x02013;CD Complex</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ks</td><td align="left" valign="middle" rowspan="1" colspan="1">Stability Constant</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">R<sup>2</sup></td><td align="left" valign="middle" rowspan="1" colspan="1">Correlation Coefficient</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x003b4; </td><td align="left" valign="middle" rowspan="1" colspan="1">Chemical Shift (for NMR spectroscopy)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ppm</td><td align="left" valign="middle" rowspan="1" colspan="1">Parts per Million</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ar-H</td><td align="left" valign="middle" rowspan="1" colspan="1">Aromatic Hydrogen</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-polymers-17-00514"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>P.C.</given-names></name>
<name><surname>Hsu</surname><given-names>Y.C.</given-names></name>
<name><surname>Hsieh</surname><given-names>M.L.</given-names></name>
<name><surname>Huang</surname><given-names>S.T.</given-names></name>
<name><surname>Huang</surname><given-names>H.C.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
</person-group><article-title>A pilot study on Trichomonas vaginalis in women with recurrent urinary tract infections</article-title><source>Biomed. J.</source><year>2016</year><volume>39</volume><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.bj.2015.11.005</pub-id><pub-id pub-id-type="pmid">27793272</pub-id>
</element-citation></ref><ref id="B2-polymers-17-00514"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loftsson</surname><given-names>T.</given-names></name>
<name><surname>Jarho</surname><given-names>P.</given-names></name>
<name><surname>M&#x000e1;sson</surname><given-names>M.</given-names></name>
<name><surname>J&#x000e4;rvinen</surname><given-names>T.</given-names></name>
</person-group><article-title>Cyclodextrins in drug delivery</article-title><source>Expert. Opin. Drug Deliv.</source><year>2005</year><volume>2</volume><fpage>335</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1517/17425247.2.1.335</pub-id><pub-id pub-id-type="pmid">16296758</pub-id>
</element-citation></ref><ref id="B3-polymers-17-00514"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Willems</surname><given-names>H.M.E.</given-names></name>
<name><surname>Ahmed</surname><given-names>S.S.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Xu</surname><given-names>Z.</given-names></name>
<name><surname>Peters</surname><given-names>B.M.</given-names></name>
</person-group><article-title>Vulvovaginal candidiasis: A current understanding and burning questions</article-title><source>J. Fungi</source><year>2020</year><volume>6</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.3390/jof6010027</pub-id><pub-id pub-id-type="pmid">32106438</pub-id>
</element-citation></ref><ref id="B4-polymers-17-00514"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>M&#x000e5;rdh</surname><given-names>P.-A.</given-names></name>
<name><surname>Rodrigues</surname><given-names>A.G.</given-names></name>
<name><surname>Gen&#x000e7;</surname><given-names>M.</given-names></name>
<name><surname>Novikova</surname><given-names>N.</given-names></name>
<name><surname>Martinez-de-Oliveira</surname><given-names>J.</given-names></name>
<name><surname>Guaschino</surname><given-names>S.</given-names></name>
</person-group><article-title>Facts and myths on recurrent vulvovaginal candidosis&#x02014;A review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy</article-title><source>Int. J. STD AIDS</source><year>2002</year><volume>13</volume><fpage>522</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1258/095646202760159639</pub-id><pub-id pub-id-type="pmid">12194734</pub-id>
</element-citation></ref><ref id="B5-polymers-17-00514"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Osma&#x00142;ek</surname><given-names>T.</given-names></name>
<name><surname>Froelich</surname><given-names>A.</given-names></name>
<name><surname>Jadach</surname><given-names>B.</given-names></name>
<name><surname>Tatarek</surname><given-names>A.</given-names></name>
<name><surname>Gadzi&#x00144;ski</surname><given-names>P.</given-names></name>
<name><surname>Falana</surname><given-names>A.</given-names></name>
<name><surname>Grali&#x00144;ska</surname><given-names>K.</given-names></name>
<name><surname>Ekert</surname><given-names>M.</given-names></name>
<name><surname>Puri</surname><given-names>V.</given-names></name>
<name><surname>Wroty&#x00144;ska-Barczy&#x00144;ska</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Recent advances in polymer-based vaginal drug delivery systems</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><elocation-id>884</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13060884</pub-id><pub-id pub-id-type="pmid">34203714</pub-id>
</element-citation></ref><ref id="B6-polymers-17-00514"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>G&#x000fc;l&#x000fc;stan</surname><given-names>F.</given-names></name>
<name><surname>Abakay</surname><given-names>M.A.</given-names></name>
<name><surname>Demir</surname><given-names>E.</given-names></name>
</person-group><article-title>Efficacy of topical isoconazole nitrate in the treatment of otomycosis</article-title><source>Am. J. Otolaryngol.</source><year>2021</year><volume>42</volume><fpage>102961</fpage><pub-id pub-id-type="doi">10.1016/j.amjoto.2021.102961</pub-id><pub-id pub-id-type="pmid">33621764</pub-id>
</element-citation></ref><ref id="B7-polymers-17-00514"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Havlickova</surname><given-names>B.</given-names></name>
<name><surname>Friedrich</surname><given-names>M.</given-names></name>
</person-group><article-title>The advantages of topical combination therapy in the treatment of inflammatory dermatomycoses</article-title><source>Mycoses</source><year>2008</year><volume>51</volume><fpage>16</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1111/j.1439-0507.2008.01615.x</pub-id><pub-id pub-id-type="pmid">18783560</pub-id>
</element-citation></ref><ref id="B8-polymers-17-00514"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jafar</surname><given-names>M.</given-names></name>
<name><surname>Khalid</surname><given-names>M.S.</given-names></name>
<name><surname>Alghamdi</surname><given-names>H.</given-names></name>
<name><surname>Amir</surname><given-names>M.</given-names></name>
<name><surname>Al Makki</surname><given-names>S.A.</given-names></name>
<name><surname>Alotaibi</surname><given-names>O.S.</given-names></name>
<name><surname>Al Rmais</surname><given-names>A.A.</given-names></name>
<name><surname>Imam</surname><given-names>S.S.</given-names></name>
<name><surname>Alshehri</surname><given-names>S.</given-names></name>
<name><surname>Gilani</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Formulation of Apigenin-Cyclodextrin-Chitosan ternary complex: Physicochemical characterization, in vitro and in vivo studies</article-title><source>AAPS PharmSciTech</source><year>2022</year><volume>23</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.1208/s12249-022-02218-8</pub-id><pub-id pub-id-type="pmid">35146576</pub-id>
</element-citation></ref><ref id="B9-polymers-17-00514"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Isadiartuti</surname><given-names>D.</given-names></name>
<name><surname>Rosita</surname><given-names>N.</given-names></name>
<name><surname>Ekowati</surname><given-names>J.</given-names></name>
<name><surname>Syahrani</surname><given-names>A.</given-names></name>
<name><surname>Ariyani</surname><given-names>T.</given-names></name>
<name><surname>Rifqi</surname><given-names>M.A.</given-names></name>
</person-group><article-title>The thermodynamic study of p-methoxycinnamic acid inclusion complex formation using &#x003b2;-cyclodextrin and hydroxypropyl-&#x003b2;-cyclodextrin</article-title><source>J. Basic Clin. Physiol. Pharmacol.</source><year>2021</year><volume>32</volume><fpage>663</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1515/jbcpp-2021-0008</pub-id><pub-id pub-id-type="pmid">34214343</pub-id>
</element-citation></ref><ref id="B10-polymers-17-00514"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peimanfard</surname><given-names>S.</given-names></name>
<name><surname>Zarrabi</surname><given-names>A.</given-names></name>
<name><surname>Trotta</surname><given-names>F.</given-names></name>
<name><surname>Matencio</surname><given-names>A.</given-names></name>
<name><surname>Cecone</surname><given-names>C.</given-names></name>
<name><surname>Caldera</surname><given-names>F.</given-names></name>
</person-group><article-title>Developing novel hydroxypropyl-&#x003b2;-cyclodextrin-based nanosponges as carriers for anticancer hydrophobic agents: Overcoming limitations of host-guest complexes in a comparative evaluation</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>1059</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14051059</pub-id><pub-id pub-id-type="pmid">35631645</pub-id>
</element-citation></ref><ref id="B11-polymers-17-00514"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yurtda&#x0015f; K&#x00131;r&#x00131;ml&#x00131;o&#x0011f;lu</surname><given-names>G.</given-names></name>
</person-group><article-title>Host-guest inclusion complex of desloratadine with 2-(hydroxy)propyl-&#x003b2;-cyclodextrin (HP-&#x003b2;-CD): Preparation, binding behaviors, and dissolution properties</article-title><source>J. Res. Pharm.</source><year>2020</year><volume>24</volume><fpage>693</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.35333/jrp.2020.224</pub-id></element-citation></ref><ref id="B12-polymers-17-00514"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kouchak</surname><given-names>M.</given-names></name>
</person-group><article-title>In situ gelling systems for drug delivery</article-title><source>Jundishapur J. Nat. Pharm. Prod.</source><year>2014</year><volume>9</volume><fpage>e20126</fpage><pub-id pub-id-type="doi">10.17795/jjnpp-20126</pub-id><pub-id pub-id-type="pmid">25237648</pub-id>
</element-citation></ref><ref id="B13-polymers-17-00514"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nirmal</surname><given-names>H.B.</given-names></name>
<name><surname>Bakliwal</surname><given-names>S.R.</given-names></name>
<name><surname>Pawar</surname><given-names>S.P.</given-names></name>
</person-group><article-title>In-situ gel: New trends in controlled and sustained drug delivery system</article-title><source>Int. J. PharmTech Res.</source><year>2010</year><volume>2</volume><fpage>1398</fpage><lpage>1408</lpage></element-citation></ref><ref id="B14-polymers-17-00514"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tu&#x0011f;cu-Demir&#x000f6;z</surname><given-names>F.</given-names></name>
</person-group><article-title>Development of in situ poloxamer-chitosan hydrogels for vaginal drug delivery of benzydamine hydrochloride: Textural, mucoadhesive and in vitro release properties</article-title><source>Marmara Pharm. J.</source><year>2017</year><volume>21</volume><fpage>762</fpage><lpage>770</lpage><comment>Available online: <ext-link xlink:href="https://dergipark.org.tr/en/pub/marupj/issue/33374/379650" ext-link-type="uri">https://dergipark.org.tr/en/pub/marupj/issue/33374/379650</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-11">(accessed on 11 February 2025)</date-in-citation></element-citation></ref><ref id="B15-polymers-17-00514"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kassem</surname><given-names>A.A.</given-names></name>
<name><surname>Ismail</surname><given-names>F.A.</given-names></name>
<name><surname>Naggar</surname><given-names>V.F.</given-names></name>
<name><surname>Aboulmagd</surname><given-names>E.</given-names></name>
</person-group><article-title>Comparative study to investigate the effect of meloxicam or minocycline HCl in situ gel system on local treatment of periodontal pockets</article-title><source>AAPS PharmSciTech</source><year>2014</year><volume>15</volume><fpage>823</fpage><pub-id pub-id-type="doi">10.1208/s12249-014-0118-7</pub-id></element-citation></ref><ref id="B16-polymers-17-00514"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takacs</surname><given-names>P.</given-names></name>
<name><surname>Kozma</surname><given-names>B.</given-names></name>
<name><surname>R&#x000e1;tonyi</surname><given-names>D.</given-names></name>
<name><surname>Kozma</surname><given-names>B.</given-names></name>
<name><surname>Attila</surname><given-names>K.S.</given-names></name>
<name><surname>Fenyvesi</surname><given-names>F.</given-names></name>
<name><surname>Sipos</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Development and bioavailability assessment of an estriol-containing vaginal hydrogel</article-title><source>Gels</source><year>2024</year><volume>10</volume><elocation-id>823</elocation-id><pub-id pub-id-type="doi">10.3390/gels10120823</pub-id><pub-id pub-id-type="pmid">39727581</pub-id>
</element-citation></ref><ref id="B17-polymers-17-00514"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bilensoy</surname><given-names>E.</given-names></name>
<name><surname>Abdur Rouf</surname><given-names>M.</given-names></name>
<name><surname>Vural</surname><given-names>I.</given-names></name>
<name><surname>H&#x00131;ncal</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole: &#x003b2;-cyclodextrin complex</article-title><source>AAPS PharmSciTech</source><year>2006</year><volume>7</volume><fpage>38</fpage><pub-id pub-id-type="doi">10.1208/pt070238</pub-id><pub-id pub-id-type="pmid">16796356</pub-id>
</element-citation></ref><ref id="B18-polymers-17-00514"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bouchemal</surname><given-names>K.</given-names></name>
<name><surname>Aka-Any-Grah</surname><given-names>A.D.</given-names></name>
<name><surname>Dereuddre-Bosquet</surname><given-names>N.</given-names></name>
<name><surname>Martin</surname><given-names>L.</given-names></name>
<name><surname>Lievin-Le-Moal</surname><given-names>V.</given-names></name>
<name><surname>Le Grand</surname><given-names>R.</given-names></name>
<name><surname>Nicolas</surname><given-names>V.</given-names></name>
<name><surname>Gibellini</surname><given-names>D.</given-names></name>
<name><surname>Lembo</surname><given-names>D.</given-names></name>
<name><surname>Po&#x000fc;s</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Thermosensitive and mucoadhesive Pluronic-hydroxypropylmethylcellulose hydrogel containing the Mini-CD4 M48U1 is a promising efficient barrier against HIV diffusion through macaque cervicovaginal mucus</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>59</volume><pub-id pub-id-type="doi">10.1128/AAC.03503-14</pub-id></element-citation></ref><ref id="B19-polymers-17-00514"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yurtda&#x0015f;</surname><given-names>G.</given-names></name>
<name><surname>Demirel</surname><given-names>M.</given-names></name>
<name><surname>Gen&#x000e7;</surname><given-names>L.</given-names></name>
</person-group><article-title>Inclusion complexes of fluconazole with &#x003b2;-cyclodextrin: Physicochemical characterization and in vitro evaluation of its formulation</article-title><source>J. Incl. Phenom. Macrocycl. Chem.</source><year>2011</year><volume>70</volume><fpage>429</fpage><lpage>435</lpage><comment>Available online: <ext-link xlink:href="https://api.semanticscholar.org/CorpusID:97064804" ext-link-type="uri">https://api.semanticscholar.org/CorpusID:97064804</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-11">(accessed on 11 February 2025)</date-in-citation></element-citation></ref><ref id="B20-polymers-17-00514"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Higuchi</surname><given-names>T.</given-names></name>
<name><surname>Connors</surname><given-names>K.A.</given-names></name>
</person-group><article-title>Phase solubility techniques</article-title><source>Adv. Anal. Chem. Instrum.</source><year>1965</year><volume>4</volume><fpage>117</fpage><lpage>210</lpage></element-citation></ref><ref id="B21-polymers-17-00514"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Makwana</surname><given-names>S.B.</given-names></name>
<name><surname>Patel</surname><given-names>V.A.</given-names></name>
<name><surname>Parmar</surname><given-names>S.J.</given-names></name>
</person-group><article-title>Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride</article-title><source>Results Pharm. Sci.</source><year>2016</year><volume>6</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.rinphs.2015.06.001</pub-id><pub-id pub-id-type="pmid">26949596</pub-id>
</element-citation></ref><ref id="B22-polymers-17-00514"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krishnamoorthy</surname><given-names>S.</given-names></name>
<name><surname>Noorani</surname><given-names>B.</given-names></name>
<name><surname>Xu</surname><given-names>C.</given-names></name>
</person-group><article-title>Effects of encapsulated cells on the physical&#x02013;mechanical properties and microstructure of gelatin methacrylate hydrogels</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>5061</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20205061</pub-id><pub-id pub-id-type="pmid">31614713</pub-id>
</element-citation></ref><ref id="B23-polymers-17-00514"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodriguez-Aller</surname><given-names>M.</given-names></name>
<name><surname>Guinchard</surname><given-names>S.</given-names></name>
<name><surname>Guillarme</surname><given-names>D.</given-names></name>
<name><surname>Pupier</surname><given-names>M.</given-names></name>
<name><surname>Jeannerat</surname><given-names>D.</given-names></name>
<name><surname>Rivara-Minten</surname><given-names>E.</given-names></name>
<name><surname>Veuthey</surname><given-names>J.L.</given-names></name>
<name><surname>Gurny</surname><given-names>R.</given-names></name>
</person-group><article-title>New prostaglandin analog formulation for glaucoma treatment containing cyclodextrins for improved stability, solubility, and ocular tolerance</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2015</year><volume>95</volume><fpage>203</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2015.04.032</pub-id><pub-id pub-id-type="pmid">25960331</pub-id>
</element-citation></ref><ref id="B24-polymers-17-00514"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Giordano</surname><given-names>F.</given-names></name>
<name><surname>Novak</surname><given-names>C.</given-names></name>
<name><surname>Moyano</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Thermal analysis of cyclodextrins and their inclusion compounds</article-title><source>Thermochim. Acta</source><year>2001</year><volume>380</volume><fpage>123</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/S0040-6031(01)00665-7</pub-id></element-citation></ref><ref id="B25-polymers-17-00514"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ribeiro</surname><given-names>A.</given-names></name>
<name><surname>Figueiras</surname><given-names>A.</given-names></name>
<name><surname>Santos</surname><given-names>D.</given-names></name>
<name><surname>Veiga</surname><given-names>F.</given-names></name>
</person-group><article-title>Preparation and solid-state characterization of inclusion complexes formed between miconazole and methyl-&#x003b2;-cyclodextrin</article-title><source>AAPS PharmSciTech</source><year>2008</year><volume>9</volume><fpage>1102</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1208/s12249-008-9143-8</pub-id><pub-id pub-id-type="pmid">18975116</pub-id>
</element-citation></ref><ref id="B26-polymers-17-00514"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Demirel</surname><given-names>M.</given-names></name>
<name><surname>Yurtda&#x0015f;</surname><given-names>G.</given-names></name>
<name><surname>Gen&#x000e7;</surname><given-names>L.</given-names></name>
</person-group><article-title>Inclusion complexes of ketoconazole with &#x003b2;-cyclodextrin: Physicochemical characterization and in vitro dissolution behaviour of its vaginal suppositories</article-title><source>J. Incl. Phenom. Macrocycl. Chem.</source><year>2011</year><volume>70</volume><fpage>437</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1007/s10847-010-9922-1</pub-id></element-citation></ref><ref id="B27-polymers-17-00514"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ol&#x02019;khovich</surname><given-names>M.V.</given-names></name>
<name><surname>Sharapova</surname><given-names>A.V.</given-names></name>
<name><surname>Perlovich</surname><given-names>G.L.</given-names></name>
<name><surname>Skachilova</surname><given-names>S.Y.</given-names></name>
<name><surname>Zheltukhin</surname><given-names>N.K.</given-names></name>
</person-group><article-title>Inclusion complex of antiasthmatic compound with 2-hydroxypropyl-&#x003b2;-cyclodextrin: Preparation and physicochemical properties</article-title><source>J. Mol. Liq.</source><year>2017</year><volume>237</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.molliq.2017.04.098</pub-id></element-citation></ref><ref id="B28-polymers-17-00514"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hang</surname><given-names>T.T.X.</given-names></name>
<name><surname>Truc</surname><given-names>T.A.</given-names></name>
<name><surname>Duong</surname><given-names>N.T.</given-names></name>
<name><surname>Vu</surname><given-names>P.G.</given-names></name>
<name><surname>Hoang</surname><given-names>T.</given-names></name>
</person-group><article-title>Preparation and characterization of nanocontainers of corrosion inhibitor based on layered double hydroxides</article-title><source>Appl. Clay Sci.</source><year>2012</year><volume>67&#x02013;68</volume><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.clay.2012.07.004</pub-id></element-citation></ref><ref id="B29-polymers-17-00514"><label>29.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Nakamoto</surname><given-names>K.</given-names></name>
</person-group><source>Applications in Coordination Chemistry. Infrared and Raman Spectra of Inorganic and Coordination Compounds, Part B: Applications in Coordination, Organometallic, and Bioinorganic Chemistry</source><publisher-name>Wiley-Interscience</publisher-name><publisher-loc>Hoboken, NJ, USA</publisher-loc><year>2008</year><fpage>1</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1002/9780470405888.ch1</pub-id></element-citation></ref><ref id="B30-polymers-17-00514"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drabi&#x00144;ska</surname><given-names>B.</given-names></name>
<name><surname>Dettlaff</surname><given-names>K.</given-names></name>
<name><surname>Ratajczak</surname><given-names>T.</given-names></name>
<name><surname>Kossakowski</surname><given-names>K.</given-names></name>
<name><surname>Chmielewski</surname><given-names>M.K.</given-names></name>
<name><surname>Cielecka-Piontek</surname><given-names>J.</given-names></name>
<name><surname>Kujawski</surname><given-names>J.</given-names></name>
</person-group><article-title>Structural and Spectroscopic Properties of Isoconazole and Bifonazole&#x02014;Experimental and Theoretical Studies</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>520</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24010520</pub-id></element-citation></ref><ref id="B31-polymers-17-00514"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Han</surname><given-names>D.</given-names></name>
<name><surname>Han</surname><given-names>Z.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Xin</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Yu</surname><given-names>Z.</given-names></name>
</person-group><article-title>Solubility enhancement of myricetin by inclusion complexation with heptakis-O-(2-hydroxypropyl)-&#x003b2;-cyclodextrin: A joint experimental and theoretical study</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>766</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21030766</pub-id><pub-id pub-id-type="pmid">31991574</pub-id>
</element-citation></ref><ref id="B32-polymers-17-00514"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Savi&#x00107;-Gaji&#x00107;</surname><given-names>I.</given-names></name>
<name><surname>Savi&#x00107;</surname><given-names>I.M.</given-names></name>
<name><surname>Nikoli&#x00107;</surname><given-names>V.D.</given-names></name>
<name><surname>Nikoli&#x00107;</surname><given-names>L.B.</given-names></name>
<name><surname>Radovanovi&#x00107;</surname><given-names>B.C.</given-names></name>
<name><surname>Mladenovi&#x00107;</surname><given-names>J.D.</given-names></name>
<name><surname>Deni&#x00107;</surname><given-names>M.S.</given-names></name>
</person-group><article-title>Study of the solubility, photostability, and structure of inclusion complexes of carvedilol with &#x003b2;-cyclodextrin and (2-hydroxypropyl)-&#x003b2;-cyclodextrin</article-title><source>J. Incl. Phenom. Macrocycl. Chem.</source><year>2016</year><volume>86</volume><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1007/s10847-016-0635-y</pub-id></element-citation></ref><ref id="B33-polymers-17-00514"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abarca</surname><given-names>R.L.</given-names></name>
<name><surname>Rodr&#x000ed;guez</surname><given-names>F.J.</given-names></name>
<name><surname>Guarda</surname><given-names>A.</given-names></name>
<name><surname>Galotto</surname><given-names>M.J.</given-names></name>
<name><surname>Bruna</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Characterization of &#x003b2;-cyclodextrin inclusion complexes containing an essential oil component</article-title><source>Food Chem.</source><year>2016</year><volume>196</volume><fpage>968</fpage><lpage>975</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2015.10.023</pub-id><pub-id pub-id-type="pmid">26593579</pub-id>
</element-citation></ref><ref id="B34-polymers-17-00514"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Radeva</surname><given-names>L.</given-names></name>
<name><surname>Yordanov</surname><given-names>Y.</given-names></name>
<name><surname>Spassova</surname><given-names>I.</given-names></name>
<name><surname>Kovacheva</surname><given-names>D.</given-names></name>
<name><surname>Tibi</surname><given-names>I.P.</given-names></name>
<name><surname>Zaharieva</surname><given-names>M.M.</given-names></name>
<name><surname>Kaleva</surname><given-names>M.</given-names></name>
<name><surname>Najdenski</surname><given-names>H.</given-names></name>
<name><surname>Petrov</surname><given-names>P.D.</given-names></name>
<name><surname>Tzankova</surname><given-names>V.</given-names></name>
<etal/>
</person-group><article-title>Incorporation of resveratrol-hydroxypropyl-&#x003b2;-cyclodextrin complexes into hydrogel formulation for wound treatment</article-title><source>Gels</source><year>2024</year><volume>10</volume><elocation-id>346</elocation-id><pub-id pub-id-type="doi">10.3390/gels10050346</pub-id><pub-id pub-id-type="pmid">38786263</pub-id>
</element-citation></ref><ref id="B35-polymers-17-00514"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Song</surname><given-names>W.</given-names></name>
<name><surname>Gu</surname><given-names>D.</given-names></name>
<name><surname>Hu</surname><given-names>Q.</given-names></name>
</person-group><article-title>Investigation of inclusion complex of cilnidipine with hydroxypropyl-&#x003b2;-cyclodextrin</article-title><source>Carbohydr. Polym.</source><year>2012</year><volume>90</volume><fpage>1719</fpage><lpage>1724</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2012.07.057</pub-id><pub-id pub-id-type="pmid">22944438</pub-id>
</element-citation></ref><ref id="B36-polymers-17-00514"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>P.-W.</given-names></name>
<name><surname>Yuan</surname><given-names>X.-F.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>B.</given-names></name>
</person-group><article-title>Preparation, characterization, and physicochemical property of the inclusion complexes of Cannabisin A with &#x003b2;-cyclodextrin and hydroxypropyl-&#x003b2;-cyclodextrin</article-title><source>J. Mol. Struct.</source><year>2023</year><volume>1272</volume><fpage>134168</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2022.134168</pub-id></element-citation></ref><ref id="B37-polymers-17-00514"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boudad</surname><given-names>H.</given-names></name>
<name><surname>Legrand</surname><given-names>P.</given-names></name>
<name><surname>Lebas</surname><given-names>G.</given-names></name>
<name><surname>Cheron</surname><given-names>M.</given-names></name>
<name><surname>Duch&#x000ea;ne</surname><given-names>D.</given-names></name>
<name><surname>Ponchel</surname><given-names>G.</given-names></name>
</person-group><article-title>Combined hydroxypropyl-&#x003b2;-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir</article-title><source>Int. J. Pharm.</source><year>2001</year><volume>218</volume><fpage>113</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(01)00622-6</pub-id><pub-id pub-id-type="pmid">11337155</pub-id>
</element-citation></ref><ref id="B38-polymers-17-00514"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Araujo</surname><given-names>D.R.</given-names></name>
<name><surname>Tsuneda</surname><given-names>S.S.</given-names></name>
<name><surname>Cereda</surname><given-names>C.M.S.</given-names></name>
<name><surname>Del</surname><given-names>G.F.</given-names></name>
<name><surname>Carvalho</surname><given-names>F.</given-names></name>
<name><surname>Pret&#x000e9;</surname><given-names>P.S.C.</given-names></name>
<name><surname>Fernandes</surname><given-names>S.A.</given-names></name>
<name><surname>Yokaichiya</surname><given-names>F.</given-names></name>
<name><surname>Franco</surname><given-names>M.K.K.D.</given-names></name>
<name><surname>Mazzaro</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Development and pharmacological evaluation of ropivacaine-2-hydroxypropyl-&#x003b2;-cyclodextrin inclusion complex</article-title><source>Eur. J. Pharm. Sci.</source><year>2008</year><volume>33</volume><fpage>60</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2007.09.010</pub-id><pub-id pub-id-type="pmid">18036789</pub-id>
</element-citation></ref><ref id="B39-polymers-17-00514"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sarwal</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>G.</given-names></name>
<name><surname>Singh</surname><given-names>S.</given-names></name>
<name><surname>Kaur</surname><given-names>L.</given-names></name>
<name><surname>Rajput</surname><given-names>S.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Tiwary</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Novel and effectual delivery of an antifungal agent for the treatment of persistent vulvovaginal candidiasis</article-title><source>J. Pharm. Investig.</source><year>2019</year><volume>49</volume><fpage>135</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1007/s40005-018-0395-3</pub-id></element-citation></ref><ref id="B40-polymers-17-00514"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ren&#x000e7;ber</surname><given-names>S.</given-names></name>
<name><surname>Karavana</surname><given-names>S.Y.</given-names></name>
<name><surname>&#x0015e;enyi&#x0011f;it</surname><given-names>Z.A.</given-names></name>
<name><surname>Era&#x000e7;</surname><given-names>B.</given-names></name>
<name><surname>Limoncu</surname><given-names>M.H.</given-names></name>
<name><surname>Balo&#x0011f;lu</surname><given-names>E.</given-names></name>
</person-group><article-title>Mucoadhesive in situ gel formulation for vaginal delivery of clotrimazole: Formulation, preparation, and in vitro/in vivo evaluation</article-title><source>Pharm. Dev. Technol.</source><year>2016</year><volume>22</volume><fpage>551</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.3109/10837450.2016.1163385</pub-id><pub-id pub-id-type="pmid">27055376</pub-id>
</element-citation></ref><ref id="B41-polymers-17-00514"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chang</surname><given-names>J.Y.</given-names></name>
<name><surname>Oh</surname><given-names>Y.-K.</given-names></name>
<name><surname>Choi</surname><given-names>H.-G.</given-names></name>
<name><surname>Kim</surname><given-names>Y.B.</given-names></name>
<name><surname>Kim</surname><given-names>C.-K.</given-names></name>
</person-group><article-title>Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions</article-title><source>Int. J. Pharm.</source><year>2002</year><volume>241</volume><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(02)00232-6</pub-id><pub-id pub-id-type="pmid">12086731</pub-id>
</element-citation></ref><ref id="B42-polymers-17-00514"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deshkar</surname><given-names>S.S.</given-names></name>
<name><surname>Patil</surname><given-names>A.T.</given-names></name>
<name><surname>Poddar</surname><given-names>S.S.</given-names></name>
</person-group><article-title>Development of thermosensitive gel of fluconazole for vaginal candidiasis</article-title><source>Int. J. Pharm. Pharm. Sci.</source><year>2015</year><volume>8</volume><fpage>391</fpage><lpage>398</lpage><comment>Available online: <ext-link xlink:href="https://api.semanticscholar.org/CorpusID:102061758" ext-link-type="uri">https://api.semanticscholar.org/CorpusID:102061758</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-02-11">(accessed on 11 February 2025)</date-in-citation></element-citation></ref><ref id="B43-polymers-17-00514"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yurtda&#x0015f;-K&#x00131;r&#x00131;ml&#x00131;o&#x0011f;lu</surname><given-names>G.</given-names></name>
</person-group><article-title>A promising approach to design thermosensitive in situ gel based on solid dispersions of desloratadine with Kolliphor<sup>&#x000ae;</sup> 188 and Pluronic<sup>&#x000ae;</sup> F127</article-title><source>J. Therm. Anal. Calorim.</source><year>2022</year><volume>147</volume><fpage>1307</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1007/s10973-020-10460-0</pub-id></element-citation></ref><ref id="B44-polymers-17-00514"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Fu</surname><given-names>M.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Xu</surname><given-names>L.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
</person-group><article-title>Synthesis of oxidized glycerol monooleate-chitosan polymer and its hydrogel formation for sustained release of trimetazidine hydrochloride</article-title><source>Int. J. Pharm.</source><year>2014</year><volume>465</volume><fpage>32</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.02.001</pub-id><pub-id pub-id-type="pmid">24508554</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="polymers-17-00514-f001"><label>Figure 1</label><caption><p>Chemical structures of (<bold>a</bold>) isoconazole nitrate (ISN), (<bold>b</bold>) hydroxypropyl-&#x003b2;-cyclodextrin (HP-&#x003b2;-CD), and (<bold>c</bold>) the proposed inclusion complex of ISN/HP-&#x003b2;-CD.</p></caption><graphic xlink:href="polymers-17-00514-g001" position="float"/></fig><fig position="float" id="polymers-17-00514-f002"><label>Figure 2</label><caption><p>Calibration curve and linearity equation of ISN standard.</p></caption><graphic xlink:href="polymers-17-00514-g002" position="float"/></fig><fig position="float" id="polymers-17-00514-f003"><label>Figure 3</label><caption><p>Phase solubility diagram of ISN/HP-&#x003b2;-CD.</p></caption><graphic xlink:href="polymers-17-00514-g003" position="float"/></fig><fig position="float" id="polymers-17-00514-f004"><label>Figure 4</label><caption><p>SEM Images of (<bold>a</bold>) pure ISN, (<bold>b</bold>) pure HP-&#x003b2;-CD, (<bold>c</bold>) physical mixture of ISN and HP-&#x003b2;-CD, and (<bold>d</bold>) ISN/HP-&#x003b2;-CD inclusion complex at 100 &#x000b5;m magnification. Insets show 200 &#x000b5;m magnification.</p></caption><graphic xlink:href="polymers-17-00514-g004" position="float"/></fig><fig position="float" id="polymers-17-00514-f005"><label>Figure 5</label><caption><p>DSC thermograms of (<bold>a</bold>) pure ISN, (<bold>b</bold>) pure HP-&#x003b2;-CD, (<bold>c</bold>) ISN/HP-&#x003b2;-CD physical mixture (PM), and (<bold>d</bold>) ISN/HP-&#x003b2;-CD inclusion complex.</p></caption><graphic xlink:href="polymers-17-00514-g005" position="float"/></fig><fig position="float" id="polymers-17-00514-f006"><label>Figure 6</label><caption><p>FT-IR spectra of (<bold>a</bold>) pure ISN, (<bold>b</bold>) pure HP-&#x003b2;-CD, (<bold>c</bold>) physical mixture of ISN and HP-&#x003b2;-CD, and (<bold>d</bold>) ISN/HP-&#x003b2;-CD inclusion complex.</p></caption><graphic xlink:href="polymers-17-00514-g006" position="float"/></fig><fig position="float" id="polymers-17-00514-f007"><label>Figure 7</label><caption><p><sup>1</sup>H-NMR spectra of (<bold>a</bold>) pure ISN, (<bold>b</bold>) pure HP-&#x003b2;-CD, (<bold>c</bold>) physical mixture of ISN and HP-&#x003b2;-CD, and (<bold>d</bold>) ISN/HP-&#x003b2;-CD inclusion complex.</p></caption><graphic xlink:href="polymers-17-00514-g007" position="float"/></fig><fig position="float" id="polymers-17-00514-f008"><label>Figure 8</label><caption><p>Rheograms of the in situ gel formulations at 25 &#x000b0;C (Day 0) (blue line: shear stress, orange line: viscosity).</p></caption><graphic xlink:href="polymers-17-00514-g008" position="float"/></fig><fig position="float" id="polymers-17-00514-f009"><label>Figure 9</label><caption><p>Rheograms of the in situ gel formulations at 37 &#x000b0;C (Day 0) (blue line: shear stress, orange line: viscosity).</p></caption><graphic xlink:href="polymers-17-00514-g009" position="float"/></fig><fig position="float" id="polymers-17-00514-f010"><label>Figure 10</label><caption><p>In vitro release profiles of in situ gel formulations containing ISN and ISN/HP-&#x003b2;-CD inclusion complex over 12 h.</p></caption><graphic xlink:href="polymers-17-00514-g010" position="float"/></fig><fig position="float" id="polymers-17-00514-f011"><label>Figure 11</label><caption><p>In vitro release profiles of in situ gel formulations containing ISN and ISN/HP-&#x003b2;-CD inclusion complex over 72 h.</p></caption><graphic xlink:href="polymers-17-00514-g011" position="float"/></fig><table-wrap position="float" id="polymers-17-00514-t001"><object-id pub-id-type="pii">polymers-17-00514-t001_Table 1</object-id><label>Table 1</label><caption><p>Components of optimal formulations (<italic toggle="yes">w</italic>/<italic toggle="yes">w</italic> %).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formulation Code</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Substance (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Pluronic<sup>&#x000ae;</sup> F127 (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HPMC(%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Benzalkonium Chloride (%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Distilled Water (%)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F12.75H05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.75</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To 100 mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To 100 mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C13.H05HP&#x003b2;CD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To 100 mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C14HP&#x003b2;CD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">To 100 mL</td></tr></tbody></table></table-wrap><table-wrap position="float" id="polymers-17-00514-t002"><object-id pub-id-type="pii">polymers-17-00514-t002_Table 2</object-id><label>Table 2</label><caption><p>Gelling capacity classification.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Observation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Coding</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No gelation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gelation occurred in a few minutes and remained for few hours</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gelation was immediate and remained for a few hours</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">++</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gelation was immediate and for an extended period</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+++</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Very stiff gel</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">++++</td></tr></tbody></table></table-wrap><table-wrap position="float" id="polymers-17-00514-t003"><object-id pub-id-type="pii">polymers-17-00514-t003_Table 3</object-id><label>Table 3</label><caption><p>Chemical shift perturbations of HP-&#x003b2;-CD in different formulations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Proton</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Complex (&#x003b4;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PM (&#x003b4;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HP-&#x003b2;-CD (&#x003b4;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;&#x003b4;<sub>1</sub> (Complex &#x02212; (HP-&#x003b2;-CD))</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">&#x00394;&#x003b4;<sub>2</sub> (PM &#x02212; (HP-&#x003b2;-CD))</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">H-1</td><td align="center" valign="middle" rowspan="1" colspan="1">4.9870</td><td align="center" valign="middle" rowspan="1" colspan="1">4.9865</td><td align="center" valign="middle" rowspan="1" colspan="1">4.985</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0020</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H-2</td><td align="center" valign="middle" rowspan="1" colspan="1">3.5218</td><td align="center" valign="middle" rowspan="1" colspan="1">3.5215</td><td align="center" valign="middle" rowspan="1" colspan="1">3.520</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0018</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H-3</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9655</td><td align="center" valign="middle" rowspan="1" colspan="1">3.9680</td><td align="center" valign="middle" rowspan="1" colspan="1">3.969</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0035</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0010</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H-4</td><td align="center" valign="middle" rowspan="1" colspan="1">3.4200</td><td align="center" valign="middle" rowspan="1" colspan="1">3.4195</td><td align="center" valign="middle" rowspan="1" colspan="1">3.418</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0020</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0015</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H-5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.7595</td><td align="center" valign="middle" rowspan="1" colspan="1">3.7610</td><td align="center" valign="middle" rowspan="1" colspan="1">3.762</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0025</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0010</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H-6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8658</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8662</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.867</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.0012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.0008</td></tr></tbody></table></table-wrap><table-wrap position="float" id="polymers-17-00514-t004"><object-id pub-id-type="pii">polymers-17-00514-t004_Table 4</object-id><label>Table 4</label><caption><p>pH measurements of in situ gel formulations containing pure ISN and ISN/HP-&#x003b2;-CD inclusion complex.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Content</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Code</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">pH</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pure ISN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F12.75H05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.04</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pure ISN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.50</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ISN/HP-&#x003b2;-CD Complex</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C13.5H05HP&#x003b2;CD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.86</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ISN/HP-&#x003b2;-CD Complex</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C14HP&#x003b2;CD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.37</td></tr></tbody></table></table-wrap><table-wrap position="float" id="polymers-17-00514-t005"><object-id pub-id-type="pii">polymers-17-00514-t005_Table 5</object-id><label>Table 5</label><caption><p>Gelling capacity of in situ gel formulations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formulation Code</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gelling Capacity</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F12.75H05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+++</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+++</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C13.H05HP&#x003b2;CD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+++</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C14HP&#x003b2;CD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">+++</td></tr></tbody></table></table-wrap><table-wrap position="float" id="polymers-17-00514-t006"><object-id pub-id-type="pii">polymers-17-00514-t006_Table 6</object-id><label>Table 6</label><caption><p>Drug content of in situ gel formulations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formulation Code</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Content (mg) &#x000b1; SE * (<italic toggle="yes">n</italic> = 3)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">F12.75H05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.615 &#x000b1; 0.044</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">F14</td><td align="center" valign="middle" rowspan="1" colspan="1">0.749 &#x000b1; 0.096</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">C13.H05HP&#x003b2;CD</td><td align="center" valign="middle" rowspan="1" colspan="1">0.655 &#x000b1; 0.142</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C14HP&#x003b2;CD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.652 &#x000b1; 0.253</td></tr></tbody></table><table-wrap-foot><fn><p>* SE: Standard error.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="polymers-17-00514-t007"><object-id pub-id-type="pii">polymers-17-00514-t007_Table 7</object-id><label>Table 7</label><caption><p>Inhibition zone diameters for antimicrobial tests of in situ gel formulations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Microorganism</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">C. albicans</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">C. glabrata</italic>
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">C. krusei</italic>
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Formulation Code</th><th colspan="3" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Zone Diameter mm</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F12.75H05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.66</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C13.5H05HP&#x003b2;CD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.00</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.33</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33.66</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35.66</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C14HP&#x003b2;CD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">38.33</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.66</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Standard deviation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.61</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.94</td></tr></tbody></table></table-wrap></floats-group></article>